Syros Pharmaceuticals (NASDAQ:SYRS) Downgraded by StockNews.com to Sell

StockNews.com lowered shares of Syros Pharmaceuticals (NASDAQ:SYRSFree Report) from a hold rating to a sell rating in a report released on Wednesday.

A number of other brokerages have also issued reports on SYRS. HC Wainwright reiterated a buy rating and issued a $15.00 price target on shares of Syros Pharmaceuticals in a report on Monday, April 1st. Piper Sandler reiterated an overweight rating and issued a $13.00 price target on shares of Syros Pharmaceuticals in a report on Wednesday, April 3rd.

Read Our Latest Stock Analysis on Syros Pharmaceuticals

Syros Pharmaceuticals Stock Performance

SYRS opened at $4.54 on Wednesday. The stock’s 50 day moving average price is $6.24 and its 200-day moving average price is $5.21. Syros Pharmaceuticals has a one year low of $2.09 and a one year high of $8.17. The company has a quick ratio of 3.95, a current ratio of 3.95 and a debt-to-equity ratio of 2.07.

Syros Pharmaceuticals (NASDAQ:SYRSGet Free Report) last released its earnings results on Wednesday, March 27th. The company reported ($1.19) EPS for the quarter, beating analysts’ consensus estimates of ($1.23) by $0.04. The firm had revenue of $0.39 million for the quarter, compared to analysts’ expectations of $2.40 million. Syros Pharmaceuticals had a negative return on equity of 227.91% and a negative net margin of 1,656.34%. On average, sell-side analysts forecast that Syros Pharmaceuticals will post -3.78 earnings per share for the current year.

Institutional Trading of Syros Pharmaceuticals

A number of hedge funds have recently bought and sold shares of SYRS. Private Advisor Group LLC purchased a new stake in Syros Pharmaceuticals during the first quarter worth $29,000. Sawtooth Solutions LLC purchased a new stake in Syros Pharmaceuticals during the first quarter worth $29,000. Prudential Financial Inc. purchased a new stake in Syros Pharmaceuticals during the second quarter worth $32,000. BNP Paribas Arbitrage SA lifted its holdings in Syros Pharmaceuticals by 540.4% during the second quarter. BNP Paribas Arbitrage SA now owns 34,608 shares of the company’s stock worth $33,000 after buying an additional 29,204 shares during the period. Finally, Two Sigma Investments LP lifted its holdings in Syros Pharmaceuticals by 30.0% during the first quarter. Two Sigma Investments LP now owns 13,600 shares of the company’s stock worth $36,000 after buying an additional 3,139 shares during the period. Hedge funds and other institutional investors own 91.47% of the company’s stock.

About Syros Pharmaceuticals

(Get Free Report)

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.

Recommended Stories

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.